Who founded Cloverbiopharma?

Cloverbiopharma was founded by Peng Liang in 2018.

Who are Cloverbiopharma's investors?

Cloverbiopharma's investors include Delos Capital.

How much funding has Cloverbiopharma raised?

Cloverbiopharma has disclosed $53.4M raised across 3 rounds.

Where is Cloverbiopharma headquartered?

Cloverbiopharma is headquartered in Chengdu.

Cloverbiopharma

Chengdu · Founded 2018 · 1 known investors

Find your way into Cloverbiopharma

850 people in our graph share verified history with the Cloverbiopharma team — schools, employers, funds. One of them is your warm intro.

Deep Nisharunlockedknows Peng Liang · together at University of Illinois Urbana-Champaign (overlapped)

×4knows the team · via The Wharton School

×2knows the team · via University of Illinois Urbana-Champaign

×3knows the team · via University of Pennsylvania

knows the team · via Harvard Medical School

knows the team · via Centerview Partners

Clover Biopharma is a commercial-stage biotechnology company that develops vaccines using its Trimer-Tag technology platform along with in-house manufacturing and commercial capabilities. Its pipeline focuses on respiratory vaccine candidates, including RSV, hMPV, and PIV3 combinations, for populations worldwide.

Biotech Healthtech

Founders & leadership

Cloverbiopharma was founded in 2018 by Peng Liang.

Peng Liang inFounderPeng Liang is founder of Clover Biopharmaceuticals and GenHunter Corporation. He was faculty in the Cancer Biology department at Vanderbilt University from 1995–2010 and conducted postdoctoral research at Harvard Medical School, where he contributed to development of Differential Display technology for gene expression analysis. Liang holds a Ph.D. in Biochemistry from the University of Illinois at Urbana-Champaign and a B.S. in Biology from Beijing University.

Joshua Liang inChief Executive Officer & Board DirectorJoshua Liang is an executive officer and director at Clover Biopharma, a biotechnology company developing vaccines using its Trimer-Tag technology platform.

Board

Xiaodong WangBoard director

Investors · 1

Delos CapitalCambridge

Reported raises · per SEC filings

Form D private placements

$53.4M disclosed across 3 rounds · 2021–2026

▶$3.6MraisedApr 2026 · 9 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Peng LiangExecutive Officer, Director, Promoter
Joshua LiangExecutive Officer, Director
Xiaodong WangDirector

Offering amount: $3.6M
Amount sold: $3.6M
First sale: Mar 2026
Incorporated: Corporation, Cayman Islands
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$904.9KraisedApr 2025 · 13 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Joshua LiangExecutive Officer, Director
Peng LiangExecutive Officer, Director, Promoter
Xiaodong WangDirector

Offering amount: $904.9K
Amount sold: $904.9K
First sale: Apr 2024
Incorporated: Corporation, Cayman Islands
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$48.9MraisedMay 2023 · 74 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Peng LiangExecutive Officer, Director, Promoter
Xiaodong WangDirector
Joshua LiangExecutive Officer, Director

Amount sold: $48.9M
First sale: Apr 2021
Incorporated: Corporation, Cayman Islands, 2018
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 4

by search overlap

Clover Health5 shared keywordsClover Health is a health insurance provider offering low-cost plans with minimal premiums, copays, and prescription drug costs. The company uses technology called Clover Assistant to help members focus on healthier living.

Vir4 shared keywordsVir Biotechnology develops treatments for infectious diseases and oncology, leveraging immunology-focused scientific capabilities. The company targets patients with unmet medical needs across these therapeutic areas.

Dynavax NASDAQ: DVAX www.dynavax.com3 shared keywordsDynavax is a commercial-stage biopharmaceutical company that develops and commercializes vaccines against infectious diseases using its adjuvant technology. Its products target immunization and infectious disease prevention.

IconOVir Bio3 shared keywordsIconovir is a biotechnology company focused on developing cancer treatments, with a stated mission to cure cancer and restore life to patients.

Companies competing with Cloverbiopharma for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Cloverbiopharma do?: Clover Biopharma is a commercial-stage biotechnology company that develops vaccines using its Trimer-Tag technology platform along with in-house manufacturing and commercial capabilities. Its pipeline focuses on respiratory vaccine candidates, including RSV, hMPV, and PIV3 combinations, for populations worldwide.
Who founded Cloverbiopharma?: Cloverbiopharma was founded by Peng Liang in 2018.
Who are Cloverbiopharma's investors?: Cloverbiopharma's investors include Delos Capital.
How much funding has Cloverbiopharma raised?: Cloverbiopharma has disclosed $53.4M raised across 3 rounds.
Where is Cloverbiopharma headquartered?: Cloverbiopharma is headquartered in Chengdu.